美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

NEWAMSTERDAM PHARMA CO NV C/WTS 22/11/2027 (TO PUR COM)

25.90

0.0000

成交量：- -

成交額：1.56萬

市值：29.17億

市盈率：-12.83

高：25.90

開：25.90

低：25.90

收：25.90

52周最高：29.99

52周最低：5.45

股本：1.13億

流通股本：1.13億

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-2.0190

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

NewAmsterdam Pharma啓動Rubens三期臨牀試驗，預計招募約300名患者，關鍵數據將於2026年底公布

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/NAMSW/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NAMSW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NAMSW\",,,,,undefined,":{"symbol":"NAMSW","market":"US","secType":"STK","nameCN":"NEWAMSTERDAM PHARMA CO NV C/WTS 22/11/2027 (TO PUR COM)","latestPrice":25.9,"timestamp":1771519803236,"preClose":25.9,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":112628458,"shares":112628458,"eps":-2.019,"marketStatus":"交易中","change":0,"latestTime":"02-19 11:50:03 EST","open":25.9,"high":25.9,"low":25.9,"amount":15629.09992,"amplitude":0,"askPrice":25.99,"askSize":100,"bidPrice":20.94,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.019,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1771534800000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":25.9,"postHourTrading":{"tag":"盘后","latestPrice":25.9,"preClose":25.97,"latestTime":"16:00 EST","volume":1,"amount":25.9,"timestamp":1771448401123,"change":-0.07,"changeRate":-0.002695,"amplitude":0},"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NAMSW\",,,,,undefined,":{"symbol":"NAMSW","floatShares":112628458,"roa":"--","roe":"--","lyrEps":0,"shares":112628458,"dividePrice":0,"high":25.9,"amplitude":0,"preClose":25.9,"low":25.9,"week52Low":5.45,"pbRate":"--","week52High":29.99,"institutionHeld":0,"latestPrice":25.9,"eps":-2.019,"divideRate":0,"volume":0,"delay":0,"ttmEps":-2.019,"open":25.9,"prevYearClose":23,"prevWeekClose":23.18,"prevMonthClose":19.45,"prevQuarterClose":23,"fiveDayClose":22.5,"twentyDayClose":22,"sixtyDayClose":28.44},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NAMSW\",params:#limit:5,,,undefined,":[{"date":"2026-02-18","symbol":"NAMSW","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1771405200000,"name":null,"time":"盤前","dateTimestamp":1771390800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NAMSW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NAMSW\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NAMSW\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1131907867","title":"NewAmsterdam Pharma啓動Rubens三期臨牀試驗，預計招募約300名患者，關鍵數據將於2026年底公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1131907867","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131907867?lang=zh_tw&edition=fundamental","pubTime":"2026-01-09 21:07","pubTimestamp":1767964048,"startTime":"0","endTime":"0","summary":"NewAmsterdam Pharma Company Nv（简称NAMSW）已正式启动其名为“Rubens”的三期临床试验。根据公司规划，该项研究预计将招募约300名患者参与，旨在评估其候选药物的有效性与安全性。\n研究团队计划在2026年底前获得关键的顶线数据结果。这一时间表的设定，为市场观察者提供了明确的研究进展预期。若试验结果积极，将有望为公司的产品管线带来重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAMSW"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":1,"code":"91000000","status":"200"}]}}